
  
    
      
        Background_NNP
        Lymphadenectomies_NNP with_IN routine_JJ histopathologic_JJ
        evaluation_NN have_VBP been_VBN performed_VBN for_IN staging_NN and_CC regional_JJ
        control_NN of_IN primary_JJ cutaneous_JJ melanoma_NN ,_, even_RB in_IN cases_NNS
        without_IN clinical_JJ evidence_NN of_IN metastasis_NNS ._. Because_IN of_IN
        significant_JJ morbidity_NN associated_VBN with_IN the_DT procedure_NN ,_,
        regional_JJ lymphadenectomy_NN has_VBZ been_VBN generally_RB recommended_VBN
        only_RB for_IN patients_NNS with_IN evidence_NN of_IN regional_JJ lymph_NN node_NN
        involvement_NN [_NN 1_CD ]_NN ._. To_TO assess_VB the_DT involvement_NN of_IN regional_JJ
        lymph_NN nodes_NNS ,_, the_DT biopsies_NNS of_IN sentinel_NN lymph_NN nodes_NNS are_VBP
        invaluable_JJ for_IN detecting_VBG occult_NN metastases_NNS without_IN the_DT
        significant_JJ morbidity_NN associated_VBN with_IN lymphadenectomy_NN [_NN 2_CD 3_CD
        4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. Previous_JJ studies_NNS have_VBP reported_VBN that_IN the_DT
        status_NN of_IN sentinel_NN lymph_NN node_NN is_VBZ an_DT accurate_JJ reflection_NN of_IN
        the_DT regional_JJ lymph_NN node_NN status_NN as_IN a_DT whole_JJ and_CC that_IN
        treatment_NN decisions_NNS can_MD be_VB made_VBN based_VBN on_IN the_DT results_NNS of_IN
        sentinel_NN lymph_NN nodes_NNS alone_RB [_NN 9_CD 10_CD 11_CD ]_NN ._.
        Previously_RB ,_, we_PRP had_VBD demonstrated_VBN higher_JJR diagnostic_JJ
        accuracy_NN in_IN detecting_VBG and_CC diagnosing_VBG melanoma_NN
        micrometastases_NNS in_IN sentinel_NN lymph_NN node_NN using_VBG monoclonal_NN
        antibodies_NNS to_TO MART-_NNP 1_CD (_( clone_NN M_NNP 2_CD -_: 7_CD C_NNP 10_CD )_) and_CC Melan-_NNP A_DT (_( clone_NN
        A_DT 103_CD )_) in_IN comparison_NN to_TO the_DT traditionally_RB used_VBN
        immunohistochemical_JJ markers_NNS ,_, S-_NNP 100_CD protein_NN (_( S-_NNP 100_CD )_) and_CC
        HMB-_NNP 45_CD [_NN 6_CD ]_NN ._. The_DT cytoplasmic_JJ staining_VBG with_IN these_DT
        immunomarkers_NNS does_VBZ not_RB obscure_VB the_DT nuclear_JJ details_NNS and_CC
        facilitates_NNS accurate_JJ interpretation_NN of_IN tumor_NN cells_NNS ,_,
        macrophages_NNS ,_, and_CC nevus_JJ cells_NNS in_IN contrast_NN to_TO S-_NNP 100_CD [_NN 6_CD 12_CD ]_NN
        ._. A_DT monoclonal_NN antibody_NN to_TO a_DT third_JJ melanoma_NN immunomarker_NN ,_,
        Tyrosinase_NNP (_( clone_NN T_NN 311_CD )_) ,_, showed_VBD an_DT immunostaining_VBG pattern_NN
        similar_JJ to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT [_NN 13_CD ]_NN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP evaluated_VBD the_DT combination_NN of_IN
        monoclonal_NN antibodies_NNS ;_: MART-_NNP 1_CD ,_, Melan-_NNP A_DT ,_, and_CC Tyrosinase_NNP in_IN
        optimized_JJ titers_NNS (_( Table_NNP 1_LS )_) for_IN evaluation_NN of_IN sentinel_NN lymph_NN
        nodes_NNS of_IN cutaneous_JJ melanoma_NN ._. We_PRP designated_VBN this_DT combination_NN
        after_IN our_PRP$ institution_NN as_IN '_POS MCW_NNP melanoma_NN cocktail_NN '_'' [_NN 6_CD 14_CD ]_NN ._.
        Hypothetically_NNP ,_, due_JJ to_TO the_DT immunoreactivity_NN of_IN the_DT cocktail_NN
        towards_IN three_CD epitopes_NNS of_IN two_CD antigens_NNS in_IN the_DT same_JJ tissue_NN
        section_NN ,_, combined_VBN use_NN of_IN these_DT immunomarkers_NNS should_MD
        increase_VB the_DT sensitivity_NN while_IN still_RB maintaining_VBG their_PRP$
        individual_JJ high_JJ specificity_NN ._. The_DT possibility_NN of_IN using_VBG a_DT
        cocktail_NN of_IN these_DT monoclonal_NN antibodies_NNS for_IN the_DT evaluation_NN
        of_IN melanoma_NN sentinel_NN lymph_NN node_NN would_MD require_VB only_RB one_CD
        section_NN as_IN compared_VBN to_TO three_CD adjacent_JJ sections_NNS for_IN each_DT of_IN
        the_DT immunomarker_NN ,_, with_IN resultant_JJ cost_NN savings_NNS of_IN
        approximately_RB two_CD thirds_NNS ._.
        The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO evaluate_VB the_DT accuracy_NN of_IN
        detecting_VBG and_CC interpreting_VBG micrometastases_NNS in_IN the_DT sentinel_NN
        lymph_NN nodes_NNS of_IN patients_NNS with_IN cutaneous_JJ melanoma_NN utilizing_VBG
        this_DT cocktail_NN in_IN a_DT single_JJ section_NN instead_RB of_IN three_CD adjacent_JJ
        sections_NNS needing_VBG each_DT of_IN the_DT three_CD immunomarkers_NNS in_IN the_DT
        cocktail_NN ._. We_PRP also_RB compared_VBD the_DT cocktail_NN against_IN MART-_NNP 1_CD and_CC
        Melan-_NNP A_DT individually_RB ._.
      
      
        Methods_NNP
        Sentinel_NNP lymph_NN node_NN specimens_NNS were_VBD grossed_JJ as_IN described_VBN
        previously_RB [_NN 6_CD ]_NN ._. Formalin-fixed_NNP paraffin-embedded_JJ tissue_NN
        sections_NNS of_IN 269_CD slices_NNS were_VBD evaluated_VBN with_IN the_DT cocktail_NN
        (_( Figure_NN 1_LS )_) ._. In_IN some_DT cases_NNS more_JJR than_IN one_CD lymph_NN nodes_NNS were_VBD
        submitted_VBN as_IN sentinel_NN lymph_NN nodes_NNS ._. The_DT fresh_JJ ,_, unfixed_JJ
        sentinel_NN lymph_NN nodes_NNS were_VBD transected_JJ into_IN slices_NNS no_RB thicker_JJR
        than_IN 3_CD mm_NN across_IN the_DT long_JJ axis_NNS from_IN one_CD pole_NN to_TO the_DT other_JJ ._.
        They_PRP were_VBD fixed_VBN flat_JJ in_IN formalin_NN after_IN wrapping_VBG them_PRP in_IN
        tissue_NN paper_NN to_TO avoid_VB curling_VBG and_CC were_VBD processed_VBN for_IN
        paraffin_NN embedding_VBG ._.
        The_DT test_NN group_NN included_VBD 188_CD slices_NNS of_IN 88_CD sentinel_NN lymph_NN
        nodes_NNS (_( 3_CD to_TO 6_CD slices_NNS per_IN lymph_NN node_NN )_) from_IN 24_CD cases_NNS (_( 1_CD to_TO 4_CD
        lymph_NN nodes_NNS per_IN case_NN )_) of_IN AJCC_NNP stage_NN I_PRP and_CC II_NNP cutaneous_JJ
        melanoma_NN lacking_VBG metastases_NNS which_WDT were_VBD easily_RB detectable_JJ in_IN
        sections_NNS stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ._. These_DT lymph_NN
        nodes_NNS were_VBD from_IN various_JJ regions_NNS other_JJ than_IN the_DT axillary_JJ
        areas_NNS ._. A_DT negative_JJ test_NN control_NN group_NN was_VBD studied_VBN to_TO verify_VB
        the_DT specificity_NN of_IN the_DT cocktail_NN ._. It_PRP consisted_VBD of_IN 81_CD slices_NNS
        of_IN 30_CD sentinel_NN lymph_NN nodes_NNS (_( 3_CD to_TO 5_CD slices_NNS per_IN lymph_NN node_NN )_)
        from_IN the_DT axillary_JJ area_NN in_IN 30_CD cases_NNS of_IN mammary_JJ carcinoma_NN ,_, of_IN
        which_WDT 40_CD slices_NNS were_VBD positive_JJ for_IN mammary_JJ carcinoma_NN
        metastases_NNS (_( Figure_NN 1_LS )_) ._.
        All_DT the_DT sections_NNS in_IN the_DT test_NN group_NN and_CC negative_JJ control_NN
        group_NN were_VBD immunostained_JJ with_IN the_DT cocktail_NN (_( the_DT details_NNS of_IN
        antibodies_NNS in_IN the_DT cocktail_NN are_VBP shown_VBN in_IN Table_NNP 1_LS )_) ._. As_IN a_DT
        standardization_NN process_NN to_TO confirm_VB positive_JJ
        immunoreactivity_NN ,_, 35_CD melanomas_NNS (_( including_VBG one_CD spindle_NN cell_NN
        melanoma_NN and_CC one_CD clear_JJ cell_NN melanoma_NN )_) were_VBD evaluated_VBN ._. All_DT
        35_CD melanomas_NNS were_VBD immunoreactive_JJ with_IN the_DT cocktail_NN ._.
        Antibodies_NNP from_IN a_DT few_JJ additional_JJ sources_NNS ,_, other_JJ than_IN those_DT
        mentioned_VBN in_IN Table_NNP 1_CD ,_, were_VBD also_RB evaluated_VBN ._. However_RB ,_, only_RB
        the_DT antibodies_NNS from_IN the_DT sources_NNS mentioned_VBN in_IN Table_NNP 1_CD with_IN
        heat_NN antigen_NN retrieval_NN protocol_NN achieved_VBD optimum_JJ results_NNS
        without_IN significant_JJ background_NN staining_VBG ._.
        The_DT sections_NNS were_VBD pretreated_JJ for_IN antigen_NN retrieval_NN using_VBG
        '_POS Dako_NNP pH_NN 6_CD ._. 0_CD target_NN retrieval_NN solution_NN '_'' ®_NN (_( Dako_NNP Corporation_NNP ,_,
        Carpinteria_NNP ,_, CA_NNP )_) at_IN 95_CD -_: 100_CD °_NN C_NNP for_IN 35_CD minutes_NNS and_CC cooled_VBN at_IN
        room_NN temperature_NN for_IN 20_CD minutes_NNS ._. The_DT target_NN retrieval_NN
        solution_NN must_MD be_VB at_IN a_DT temperature_NN of_IN 95_CD -_: 100_CD °_NN C_NNP from_IN the_DT
        start_NN ._. The_DT duration_NN of_IN this_DT heat_NN antigen_NN retrieval_NN step_NN was_VBD
        crucial_JJ for_IN avoiding_VBG non-specific_JJ background_NN staining_VBG ._. It_PRP
        was_VBD optimal_NN for_IN all_PDT the_DT three_CD antibodies_NNS in_IN the_DT
        cocktail_NN ._.
        Three-micron_NNP thick_JJ serial_NN sections_NNS of_IN paraffin-embedded_JJ
        tissue_NN blocks_NNS were_VBD numbered_VBN consecutively_RB from_IN 1_CD to_TO 3_CD ._.
        Section_NN #_# 1_CD was_VBD stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ._. Section_NN
        #_# 2_CD was_VBD immunostained_JJ with_IN '_POS melanoma_NN cocktail_NN '_'' using_VBG
        Diaminobenzidine_NNP Hydrochloride_NNP (_( DAB_NNP )_) as_IN a_DT chromogen_NN ._.
        Section_NN #_# 3_CD was_VBD used_VBN as_IN a_DT negative_JJ control_NN without_IN primary_JJ
        antibody_NN ._. A_DT positive_JJ control_NN consisting_VBG of_IN a_DT formalin-fixed_JJ
        paraffin-embedded_JJ tissue_NN section_NN of_IN melanoma_NN demonstrating_VBG
        reactivity_NN for_IN the_DT cocktail_NN was_VBD processed_VBN with_IN each_DT batch_NN
        of_IN slides_NNS ._. Two_CD adjacent_JJ sections_NNS were_VBD immunostained_JJ with_IN
        MART-_NNP 1_CD and_CC Melan-_NNP A_DT respectively_RB during_IN our_PRP$ previous_JJ study_NN
        on_IN 78_CD out_IN of_IN 188_CD slices_NNS (_( from_IN 14_CD cases_NNS )_) [_NN 6_CD ]_NN ._. The_DT
        immediately_RB adjacent_JJ unstained_JJ sections_NNS during_IN the_DT previous_JJ
        study_NN were_VBD used_VBN ._. They_PRP were_VBD immunostained_JJ with_IN the_DT cocktail_NN
        in_IN this_DT study_NN ._.
        Five_CD pathologists_NNS interpreted_VBD all_DT immunostained_JJ slides_NNS
        independently_RB to_TO determine_VB the_DT presence_NN of_IN melanoma_NN
        micrometastases_NNS ._. Whenever_WRB indicated_VBD ,_, respective_JJ adjacent_JJ
        hematoxylin_NN and_CC eosin_NN stained_JJ sections_NNS and_CC negative_JJ control_NN
        sections_NNS were_VBD also_RB used_VBN to_TO facilitate_VB the_DT final_JJ
        interpretation_NN ._.
        Statistical_NNP evaluation_NN for_IN degree_NN of_IN interobserver_NN
        agreement_NN was_VBD based_VBN on_IN the_DT Receiver_NNP Operating_NNP
        Characteristic_NNP (_( ROC_NNP )_) curve_NN ,_, which_WDT takes_VBZ into_IN consideration_NN
        the_DT non-binary_JJ spectrum_NN of_IN surgical_JJ pathology_NN
        interpretation_NN [_NN 6_CD 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN ._. For_IN the_DT generation_NN of_IN
        the_DT ROC_NNP curve_NN and_CC to_TO calculate_VB the_DT areas_NNS under_IN the_DT ROC_NNP
        curves_NNS (_( Az_NNP values_NNS )_) ,_, the_DT spectrum_NN of_IN the_DT interpretation_NN was_VBD
        spread_VBN into_IN five_CD points_NNS with_IN negative_JJ and_CC positive_JJ at_IN each_DT
        end_NN [_NN 6_CD ]_NN ._.
        A_DT consensus_NN binary_JJ negative_JJ or_CC positive_JJ diagnosis_NN was_VBD
        reached_VBN by_IN all_DT five_CD pathologists_NNS in_IN tandem_JJ under_IN a_DT
        multihead_NN microscope_NN ._. This_DT was_VBD used_VBN as_IN the_DT final_JJ diagnosis_NN
        for_IN statistical_JJ analysis_NN ._. Az_NNP values_NNS by_IN different_JJ observers_NNS
        for_IN 188_CD sections_NNS were_VBD compared_VBN using_VBG non-parametric_JJ methods_NNS
        based_VBN on_IN the_DT Mann-_NNP Whitney_NNP statistics_NNS [_NN 20_CD ]_NN ._. SAS_NNP
        statistical_JJ software_NN (_( The_DT SAS_NNP institute_NN ,_, Cary_NNP ,_, NC_NNP )_) was_VBD
        implemented_VBN for_IN this_DT statistical_JJ analysis_NN (_( Table_NNP 2_LS )_) ._.
      
      
        Results_NNS
        Of_IN the_DT 188_CD sections_NNS immunostained_JJ with_IN '_POS melanoma_NN
        cocktail_NN '_'' ,_, 41_CD sections_NNS (_( 8_CD /_NN 24_CD cases_NNS )_) were_VBD positive_JJ for_IN
        melanoma_NN micrometastases_NNS (_( Figure_NN 2_CD A_DT &_CC 2_CD B_NNP )_) ._. Az_NNP values_NNS for_IN
        the_DT cocktail_NN by_IN all_DT five_CD pathologists_NNS were_VBD high_JJ and_CC ranged_VBD
        from_IN 0_CD ._. 8525_CD to_TO 1_CD ._. 000_CD (_( maximum_NN possible_JJ Az_NNP value_NN is_VBZ 1_CD ._. 000_CD )_)
        without_IN statistically_RB significant_JJ differences_NNS (_( p_NN ._. 0743_CD )_)
        (_( Table_NNP 2_LS )_) ._.
        In_IN general_JJ ,_, the_DT micrometastases_NNS were_VBD subtle_JJ and_CC
        difficult_JJ to_TO detect_VB in_IN the_DT hematoxylin_NN and_CC eosin_NN stained_JJ
        sections_NNS alone_RB ._. Depending_VBG on_IN the_DT observer_NN ,_, micrometastases_NNS
        of_IN melanoma_NN in_IN 41_CD slices_NNS were_VBD detectable_JJ in_IN only_RB 30_CD -_: 45_CD %_NN of_IN
        hematoxylin_NN and_CC eosin_NN sections_NNS ._. However_RB ,_, with_IN closer_RBR
        methodical_JJ scrutiny_NN ,_, these_DT micrometastases_NNS were_VBD seen_VBN
        retrospectively_RB in_IN all_DT 41_CD adjacent_JJ sections_NNS stained_JJ with_IN
        hematoxylin_NN and_CC eosin_NN ._. All_DT 81_CD sections_NNS from_IN sentinel_NN lymph_NN
        nodes_NNS of_IN mammary_JJ carcinoma_NN in_IN the_DT negative_JJ test_NN control_NN
        group_NN (_( Figure_NN 1_LS )_) were_VBD interpreted_VBN unequivocally_RB as_IN negative_JJ
        for_IN melanoma_NN micrometastases_NNS by_IN each_DT of_IN the_DT five_CD
        pathologists_NNS (_( Figure_NN 2_CD C_NNP )_) ._.
        Out_IN of_IN 188_CD slices_NNS ,_, a_DT pool_NN of_IN sections_NNS immunostained_JJ
        individually_RB with_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT during_IN our_PRP$ previous_JJ
        study_NN (_( Figure_NN 1_LS )_) were_VBD compared_VBN with_IN the_DT cocktail_NN ._. Melanoma_NNP
        micrometastases_NNS were_VBD detected_VBN in_IN 21_CD of_IN 78_CD slices_NNS
        immunostained_JJ with_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT individually_RB ._.
        However_RB ,_, 25_CD slices_NNS demonstrated_VBD micrometastases_NNS with_IN the_DT
        cocktail_NN ._. These_DT four_CD slices_NNS (_( from_IN 2_CD lymph_NN nodes_NNS of_IN 2_CD
        cases_NNS )_) ,_, negative_JJ for_IN micrometastases_NNS with_IN MART-_NNP 1_CD and_CC
        Melan-_NNP A_DT ,_, showed_VBD melanoma_NN micrometastases_NNS predominantly_RB as_IN
        single_JJ cells_NNS ._. These_DT micrometastases_NNS were_VBD detectable_JJ
        retrospectively_RB in_IN adjacent_JJ sections_NNS stained_JJ with_IN
        hematoxylin_NN and_CC eosin_NN in_IN all_DT four_CD slices_NNS ._. Thus_RB ,_, MART-_NNP 1_CD and_CC
        Melan-_NNP A_DT individually_RB could_MD not_RB detect_VB micrometastases_NNS in_IN
        16_CD %_NN (_( 4_CD /_NN 25_CD )_) of_IN the_DT slices_NNS ._. No_DT sections_NNS which_WDT were_VBD negative_JJ
        for_IN micrometastases_NNS with_IN the_DT cocktail_NN demonstrated_VBD
        micrometastases_NNS with_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT individually_RB ._.
        The_NNP '_POS melanoma_NN cocktail_NN '_'' did_VBD not_RB show_VB background_NN staining_VBG
        of_IN non-melanocytic_JJ cells_NNS in_IN the_DT sentinel_NN lymph_NN nodes_NNS
        (_( Figure_NN 2_CD and_CC 3_LS )_) and_CC demonstrated_VBN immunostaining_VBG pattern_NN
        identical_JJ to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT reported_VBD previously_RB [_NN 6_CD ]_NN ._.
        5_CD %_NN (_( 9_CD /_NN 188_CD )_) slices_NNS from_IN 21_CD %_NN (_( 5_CD /_NN 24_CD )_) of_IN the_DT cases_NNS showed_VBD
        groups_NNS of_IN cohesive_JJ spindle_NN cells_NNS which_WDT were_VBD immunoreactive_JJ
        for_IN the_DT cocktail_NN in_IN the_DT capsule_NN of_IN sentinel_NN lymph_NN nodes_NNS ._.
        The_DT bland_JJ nuclear_JJ morphology_NN of_IN these_DT spindle_NN cells_NNS was_VBD
        consistent_JJ with_IN benign_JJ capsular_NN melanocytic_JJ nevi_NN (_( Figure_NN
        3_LS )_) ._. None_NN of_IN the_DT 81_CD sections_NNS of_IN sentinel_NN lymph_NN nodes_NNS from_IN 30_CD
        cases_NNS of_IN mammary_JJ carcinoma_NN demonstrated_VBD benign_JJ capsular_NN
        melanocytic_JJ nevi_NN ._.
      
      
        Discussion_NNP
        At_IN present_JJ histomorphologic_JJ examination_NN with_IN
        immunohistochemistry_NN remains_VBZ the_DT most_RBS reliable_JJ and_CC
        practical_JJ means_NNS of_IN detecting_VBG melanoma_NN micrometastases_NNS in_IN
        sentinel_NN lymph_NN nodes_NNS [_NN 6_CD 21_CD ]_NN ._. MART-_NNP 1_CD and_CC Melan-_NNP A_DT are_VBP two_CD
        antibodies_NNS to_TO different_JJ epitopes_NNS of_IN the_DT same_JJ antigen_NN and_CC
        are_VBP complementary_JJ to_TO each_DT other_JJ ._. As_IN previously_RB reported_VBN ,_,
        MART-_NNP 1_CD and_CC Melan-_NNP A_DT demonstrated_VBN predominantly_RB cytoplasmic_JJ
        staining_VBG of_IN melanoma_NN cells_NNS [_NN 6_CD ]_NN ._. The_DT monoclonal_NN antibody_NN
        (_( T_NN 311_CD )_) to_TO tyrosinase_NN ,_, has_VBZ been_VBN reported_VBN to_TO demonstrate_VB high_JJ
        sensitivity_NN and_CC specificity_NN for_IN melanoma_NN [_NN 13_CD ]_NN ._. It_PRP has_VBZ
        also_RB demonstrated_VBN an_DT immunostaining_VBG pattern_NN in_IN sentinel_NN
        lymph_NN nodes_NNS identical_JJ to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT ._. We_PRP combined_VBD
        these_DT three_CD antibodies_NNS as_IN '_POS MCW_NNP melanoma_NN cocktail_NN '_'' (_( Table_NNP
        1_LS )_) ._.
        In_IN contrast_NN to_TO S-_NNP 100_CD ,_, these_DT immunomarkers_NNS did_VBD not_RB
        obscure_JJ nuclear_JJ details_NNS ._. In_IN addition_NN ,_, they_PRP did_VBD not_RB stain_VB
        the_DT dendritic_JJ cells_NNS which_WDT are_VBP generally_RB prominent_JJ in_IN the_DT
        sentinel_NN lymph_NN nodes_NNS after_IN the_DT diagnostic_JJ biopsy_NN of_IN a_DT
        primary_JJ lesion_NN ._. This_DT facilitated_JJ unequivocal_NN interpretation_NN
        of_IN singly_RB scattered_VBN melanoma_NN cells_NNS which_WDT were_VBD otherwise_RB
        impossible_JJ to_TO identify_VB in_IN sections_NNS immunostained_JJ for_IN S-_NNP 100_CD
        due_JJ to_TO high_JJ noise_NN to_TO signal_VB ratio_NN resulting_VBG from_IN numerous_JJ
        S-_NNP 100_CD immunoreactive_JJ dendritic_JJ cells_NNS in_IN the_DT background_NN ._.
        Thus_RB ,_, a_DT highly_RB sensitive_JJ immunomarker_NN such_JJ as_IN S-_NNP 100_CD is_VBZ less_RBR
        effective_JJ for_IN interpretation_NN of_IN sentinel_NN lymph_NN nodes_NNS for_IN
        melanoma_NN micrometastases_NNS (_( especially_RB when_WRB present_JJ as_IN single_JJ
        cells_NNS )_) than_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT [_NN 6_CD ]_NN ._. Certain_NNP
        morphological_JJ features_NNS help_VBP to_TO differentiate_VB melanoma_NN cells_NNS
        and_CC other_JJ non-melanoma_JJ cells_NNS such_JJ as_IN S_NNP 100_CD immunoreactive_JJ
        dendritic_JJ cells_NNS in_IN sentinel_NN lymph_NN nodes_NNS ._. However_RB ,_, as_IN
        demonstrated_VBN in_IN our_PRP$ previous_JJ study_NN ,_, it_PRP is_VBZ not_RB uncommon_JJ to_TO
        face_VB an_DT equivocal_NN situation_NN when_WRB S-_NNP 100_CD protein_NN is_VBZ used_VBN as_IN
        an_DT immunomarker_NN for_IN the_DT interpretation_NN of_IN single_JJ melanoma_NN
        micrometastases_NNS in_IN sentinel_NN lymph_NN nodes_NNS [_NN 6_CD ]_NN ._. Based_VBN on_IN
        our_PRP$ previous_JJ study_NN with_IN HMB_NNP 45_CD [_NN 6_CD ]_NN and_CC an_DT initial_JJ study_NN
        with_IN micropthalmia_NN transcription_NN factor_NN [_NN 22_CD ]_NN ,_, these_DT
        immunomarkers_NNS were_VBD not_RB considered_VBN suitable_JJ for_IN inclusion_NN in_IN
        the_DT cocktail_NN due_JJ to_TO the_DT immunoreactivity_NN of_IN non-melanoma_JJ
        cells_NNS in_IN the_DT sentinel_NN lymph_NN nodes_NNS ._.
        During_IN further_RBR evaluation_NN ,_, we_PRP confirmed_VBD that_IN the_DT single_JJ
        cells_NNS immunostained_JJ with_IN HMB_NNP 45_CD were_VBD mast_NN cells_NNS and_CC not_RB
        melanophages_NNS ._. Although_IN not_RB reported_VBD in_IN the_DT literature_NN ,_, mast_NN
        cells_NNS in_IN mastocytosis_NNS and_CC reactive_JJ mast_NN cells_NNS in_IN desmoid_NN
        tumors_NNS also_RB showed_VBD immunoreactivity_NN for_IN HMB_NNP 45_CD with_IN granular_JJ
        cytoplasmic_JJ immunostaining_VBG pattern_NN ._. The_DT same_JJ cells_NNS in_IN the_DT
        immediately_RB adjacent_JJ section_NN were_VBD confirmed_VBN as_IN mast_NN cell_NN by_IN
        CD_NNP 117_CD (_( personal_JJ experience_NN )_) ._. Lack_NN of_IN similar_JJ staining_VBG in_IN
        the_DT negative_JJ control_NN sections_NNS excludes_VBZ their_PRP$ non-specific_JJ
        nature_NN ._. Mast_NNP cells_NNS are_VBP relatively_RB frequent_JJ in_IN sentinel_NN
        lymph_NN nodes_NNS ,_, likely_JJ secondary_JJ to_TO the_DT previous_JJ biopsy_NN in_IN the_DT
        draining_VBG field_NN (_( personal_JJ experience_NN )_) ._. Occasionaly_NNP these_DT
        cells_NNS may_MD present_VB an_DT interpretation_NN challenge_NN ,_, but_CC they_PRP can_MD
        usually_RB be_VB interpreted_VBN as_IN benign_JJ [_NN 6_CD ]_NN ._. To_TO avoid_VB this_DT
        interference_NN by_IN HMB_NNP 45_CD and_CC its_PRP$ lower_JJR sensitivity_NN in_IN general_JJ ,_,
        HMB_NNP 45_CD was_VBD not_RB incorporated_VBN in_IN the_DT cocktail_NN ._.
        Out_IN of_IN 188_CD sections_NNS immunostained_JJ with_IN the_DT cocktail_NN and_CC
        interpreted_VBN by_IN all_DT five_CD pathologists_NNS collectively_RB ,_, 41_CD were_VBD
        positive_JJ for_IN melanoma_NN micrometastases_NNS (_( Figure_NN 2_CD Aand_NNP 2_CD B_NNP )_) ._. Az_NNP
        values_NNS amongst_IN the_DT five_CD pathologists_NNS interpreting_VBG these_DT
        sections_NNS independently_RB did_VBD not_RB show_VB statistically_RB
        significant_JJ differences_NNS ,_, demonstrating_VBG excellent_JJ
        interobserver_NN agreement_NN with_IN the_DT cocktail_NN (_( Table_NNP 2_LS )_) ._. None_NN
        of_IN the_DT 81_CD sections_NNS of_IN mammary_JJ carcinoma_NN sentinel_NN lymph_NN
        nodes_NNS showed_VBD immunoreactivity_NN for_IN the_DT cocktail_NN in_IN any_DT of_IN
        the_DT non-melanoma_JJ cells_NNS (_( Figure_NN 2_CD C_NNP )_) and_CC were_VBD interpreted_VBN as_IN
        negative_JJ for_IN melanoma_NN micrometastases_NNS by_IN all_DT five_CD
        observers_NNS ._.
        The_DT cocktail_NN showed_VBD favorable_JJ detection_NN rate_NN for_IN
        melanoma_NN micrometastases_NNS as_IN compared_VBN to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT
        alone_RB ._. Of_IN 78_CD sections_NNS ,_, 25_CD sections_NNS were_VBD positive_JJ for_IN
        melanoma_NN micrometastases_NNS with_IN the_DT cocktail_NN ._. However_RB ,_, only_RB
        21_CD were_VBD positive_JJ with_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT individually_RB ._.
        Thus_RB ,_, MART-_NNP 1_CD and_CC Melan-_NNP A_DT could_MD not_RB individually_RB detect_VB
        melanoma_NN micrometastases_NNS in_IN 16_CD %_NN (_( 4_CD /_NN 25_CD )_) of_IN slices_NNS that_WDT were_VBD
        positive_JJ for_IN melanoma_NN micrometastases_NNS with_IN the_DT cocktail_NN ._. As_IN
        expected_VBN ,_, combining_VBG a_DT monoclonal_NN antibody_NN to_TO tyrosinase_NN
        with_IN MART-_NNP 1_CD and_CC Melan-_NNP A_DT in_IN the_DT cocktail_NN increased_VBD the_DT
        spectrum_NN to_TO encompass_VB three_CD epitopes_NNS of_IN two_CD melanoma_NN
        antigens_NNS (_( MART-_NNP 1_CD /_NN Melan-_NNP A_DT and_CC tyrosinase_NN )_) ._. If_IN indicated_VBD in_IN
        the_DT future_JJ ,_, additional_JJ monoclonal_NN antibodies_NNS showing_VBG
        immunostaining_VBG patterns_NNS in_IN sentinel_NN lymph_NN nodes_NNS that_WDT are_VBP
        similar_JJ to_TO these_DT three_CD antibodies_NNS which_WDT also_RB posess_NNS high_JJ
        specificity_NN for_IN melanoma_NN may_MD be_VB added_VBN to_TO this_DT cocktail_NN ,_, by_IN
        widening_VBG the_DT spectrum_NN for_IN many_JJ melanoma_NN specific_JJ antigen_NN
        epitopes_NNS ._. However_RB ,_, care_NN should_MD be_VB taken_VBN to_TO not_RB include_VB any_DT
        antibody_NN that_WDT may_MD immunostain_NN other_JJ non-melanoma_JJ cells_NNS in_IN
        the_DT sentinel_NN lymph_NN nodes_NNS ._. Otherwise_RB ,_, such_JJ antibodies_NNS may_MD
        contribute_VB to_TO the_DT deterioration_NN in_IN the_DT specificity_NN of_IN the_DT
        cocktail_NN compromising_VBG its_PRP$ application_NN for_IN evaluation_NN of_IN the_DT
        sentinel_NN lymph_NN nodes_NNS of_IN melanoma_NN ._.
        During_IN the_DT standardization_NN ,_, all_DT 35_CD melanomas_NNS (_( including_VBG
        one_CD spindle_NN cell_NN melanoma_NN and_CC one_CD clear_JJ cell_NN melanoma_NN )_) were_VBD
        immunoreactive_JJ with_IN '_POS the_DT cocktail_NN '_'' ._. Non-immunoreactivity_NNP of_IN
        special_JJ variants_NNS of_IN melanoma_NN to_TO various_JJ melanoma_NN
        immunomarkers_NNS is_VBZ a_DT challenge_NN ._. During_IN interpretation_NN of_IN
        sentinel_NN lymph_NN nodes_NNS ,_, the_DT diagnosis_NN of_IN melanoma_NN is_VBZ known_VBN
        and_CC the_DT aim_NN is_VBZ to_TO detect_VB the_DT melanoma_NN micrometastases_NNS of_IN
        the_DT known_VBN primary_JJ ._. If_IN the_DT sentinel_NN lymph_NN nodes_NNS of_IN special_JJ
        variants_NNS of_IN melanoma_NN are_VBP negative_JJ by_IN '_POS the_DT cocktail_NN '_'' ,_, it_PRP
        would_MD be_VB prudent_JJ to_TO confirm_VB the_DT immunoreactivity_NN of_IN the_DT
        primary_JJ lesion_NN for_IN '_POS the_DT cocktail_NN '_'' ._. If_IN the_DT primary_JJ melanoma_NN
        is_VBZ non-immunoreactive_JJ for_IN '_POS the_DT cocktail_NN '_'' ,_, the_DT negative_JJ
        interpretation_NN of_IN the_DT sentinel_NN lymph_NN nodes_NNS with_IN cocktail_NN in_IN
        this_DT situation_NN may_MD be_VB confirmed_VBN with_IN other_JJ suitable_JJ
        immunomarker_NN to_TO which_WDT the_DT primary_JJ melanoma_NN is_VBZ
        immunoreactive_JJ ._. The_DT cocktail_NN was_VBD not_RB compared_VBN with_IN S-_NNP 100_CD in_IN
        this_DT study_NN ,_, as_IN its_PRP$ role_NN in_IN evaluation_NN of_IN sentinel_NN lymph_NN
        nodes_NNS of_IN melanoma_NN was_VBD already_RB demonstrated_VBN to_TO be_VB unreliable_JJ
        even_RB in_IN comparison_NN to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT individually_RB in_IN
        the_DT previous_JJ study_NN [_NN 6_CD ]_NN ._. We_PRP did_VBD not_RB compare_VB tyrosinase_NN
        alone_RB with_IN the_DT cocktail_NN because_IN the_DT questionable_JJ
        contribution_NN of_IN such_JJ a_DT study_NN would_MD not_RB be_VB offset_VBN by_IN the_DT
        additional_JJ cost_NN involved_VBN ._. Published_VBN studies_NNS do_VBP not_RB report_VB
        100_CD %_NN immunostaining_VBG with_IN anti-tyrosinase_JJ antibody_NN (_( T_NN 311_CD )_) ._.
        Tyrosinase_NNP alone_RB or_CC any_DT other_JJ immunomarker_NN used_VBN
        individually_RB ,_, would_MD be_VB less_RBR sensitive_JJ than_IN a_DT cocktail_NN ._. To_TO
        evaluate_VB the_DT exact_JJ impact_NN of_IN the_DT cocktail_NN in_IN comparison_NN to_TO
        all_DT of_IN its_PRP$ component_NN immunomarkers_NNS individually_RB for_IN
        evaluation_NN of_IN sentinel_NN lymph_NN nodes_NNS ,_, additional_JJ studies_NNS
        dedicated_VBN to_TO comparison_NN of_IN individual_JJ component_NN
        immunomarkers_NNS with_IN the_DT cocktail_NN may_MD be_VB called_VBN for_IN ._.
        Capsular_NNP nevi_NN in_IN the_DT form_NN of_IN a_DT few_JJ cohesive_JJ cocktail_NN
        immunoreactive_JJ spindle_NN cells_NNS with_IN bland_JJ elongated_JJ nuclei_NN
        (_( Figure_NN 3_LS )_) were_VBD observed_VBN in_IN 5_CD %_NN (_( 9_CD /_NN 188_CD )_) of_IN sections_NNS (_( 10_CD %_NN
        (_( 9_CD /_NN 88_CD )_) of_IN sentinel_NN lymph_NN nodes_NNS and_CC 21_CD %_NN (_( 5_CD /_NN 24_CD )_) of_IN cases_NNS ._. As_IN
        compared_VBN to_TO this_DT ,_, none_NN of_IN the_DT 81_CD slices_NNS of_IN sentinel_NN lymph_NN
        nodes_NNS from_IN 30_CD cases_NNS of_IN mammary_JJ carcinoma_NN showed_VBD capsular_NN
        melanocytic_JJ nevi_NN ._. The_DT sentinel_NN lymph_NN nodes_NNS of_IN melanocytic_JJ
        nevi_NN were_VBD from_IN different_JJ sites_NNS and_CC none_NN were_VBD from_IN the_DT
        axillary_JJ region_NN ._. The_DT exact_JJ explanation_NN for_IN this_DT difference_NN
        in_IN the_DT prevalence_NN of_IN capsular_NN nevi_NN could_MD not_RB be_VB deciphered_JJ
        and_CC further_JJ evaluation_NN is_VBZ in_IN process_NN ._. The_DT association_NN of_IN
        higher_JJR frequency_NN of_IN capsular_NN melanocytic_JJ nevi_NN with_IN
        congenital_NN nevi_NN [_NN 23_CD ]_NN is_VBZ one_CD possibility_NN ._. In_IN our_PRP$ study_NN ,_,
        except_IN for_IN the_DT difference_NN in_IN their_PRP$ regional_JJ variation_NN ,_,
        another_DT possible_JJ explanation_NN is_VBZ the_DT cytokine_NN effect_NN of_IN the_DT
        melanoma_NN draining_VBG to_TO the_DT sentinel_NN lymph_NN node_NN ._.
        Hypothetically_NNP ,_, an_DT association_NN between_IN the_DT higher_JJR
        prevalence_NN of_IN melanocytic_JJ capsular_NN nevi_NN and_CC the_DT
        predisposition_NN for_IN melanoma_NN may_MD be_VB likely_JJ ._. Although_IN ,_, these_DT
        melanocytic_JJ capsular_NN nevi_NN appear_VBP benign_JJ morphologically_RB ,_, a_DT
        low_JJ probability_NN that_IN they_PRP may_MD represent_VB subtle_JJ metastases_NNS
        was_VBD also_RB considered_VBN ._. Further_RB evaluation_NN of_IN these_DT and_CC other_JJ
        possibilities_NNS in_IN larger_JJR series_NN is_VBZ recommended_VBN ._.
        Using_VBG immunohistochemistry_NN ,_, Yu_NNP et_CC al_NN [_NN 8_CD ]_NN reported_VBD
        capsular_NN benign_JJ melanocytic_JJ nevi_NN in_IN 4_CD %_NN (_( 9_CD /_NN 235_CD )_) of_IN sentinel_NN
        lymph_NN nodes_NNS of_IN melanoma_NN from_IN 9_CD %_NN (_( 8_CD /_NN 94_CD )_) cases_NNS (_( some_DT cases_NNS
        had_VBD more_JJR than_IN one_CD sentinel_NN lymph_NN node_NN )_) ._. Capsular_NNP
        melanocytic_JJ nevi_NN appear_VBP to_TO be_VB the_DT most_RBS significant_JJ benign_JJ
        lesion_NN that_WDT could_MD pose_VB a_DT diagnostic_JJ challenge_NN in_IN the_DT
        interpretation_NN of_IN melanoma_NN micrometastases_NNS in_IN sentinel_NN
        lymph_NN nodes_NNS ._. For_IN similar_JJ reasons_NNS ,_, non-in-situ_JJ molecular_JJ
        techniques_NNS ,_, such_JJ as_IN RT-PCR_NNP [_NN 6_CD 8_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN would_MD
        have_VB higher_JJR tendencies_NNS for_IN false_JJ positive_JJ results_NNS ._.
        Morphology_NNP appears_VBZ to_TO be_VB the_DT single_JJ most_RBS important_JJ tool_NN
        facilitating_VBG their_PRP$ correct_JJ interpretation_NN [_NN 6_CD ]_NN ._. Other_JJ
        approaches_NNS ,_, including_VBG the_DT observation_NN that_DT capsular_NN nevi_NN
        are_VBP non-immunoreactive_JJ or_CC weakly_RB immunoreactive_JJ for_IN HMB_NNP 45_CD ,_,
        have_VBP been_VBN suggested_VBN for_IN differentiating_VBG capsular_NN nevi_NN from_IN
        melanoma_NN micrometastases_NNS [_NN 21_CD ]_NN ._. However_RB ,_, it_PRP is_VBZ important_JJ
        to_TO note_VB that_IN a_DT significant_JJ number_NN of_IN melanomas_NNS are_VBP also_RB
        non-immunoreactive_JJ for_IN HMB_NNP 45_CD ._. Thus_RB ,_, strong_JJ immunoreactivity_NN
        for_IN HMB_NNP 45_CD rules_NNS out_IN capsular_NN nevus_JJ ,_, but_CC
        non-immunoreactivity_JJ may_MD not_RB be_VB contributory_NN ._.
        Rather_RB than_IN immunostaining_VBG three_CD adjacent_JJ sections_NNS with_IN
        individual_JJ antibodies_NNS in_IN the_DT cocktail_NN ,_, only_RB one_CD slide_NN is_VBZ
        required_VBN which_WDT leads_VBZ to_TO cost_VB savings_NNS ._. Although_IN ,_, the_DT cost_NN of_IN
        the_DT three_CD antibodies_NNS used_VBN in_IN the_DT cocktail_NN has_VBZ to_TO be_VB
        incurred_VBN ,_, the_DT material_NN and_CC labor_NN cost_NN savings_NNS for_IN one_CD
        instead_RB of_IN three_CD slides_NNS is_VBZ obvious_JJ ._. For_IN proper_JJ sampling_VBG ,_,
        some_DT studies_NNS recommend_VBP the_DT evaluation_NN of_IN three_CD levels_NNS at_IN
        200_CD μ_NN intervals_NNS [_NN 30_CD ]_NN ._. In_IN that_DT case_NN ,_, if_IN each_DT of_IN the_DT three_CD
        antibodies_NNS in_IN the_DT cocktail_NN had_VBD to_TO be_VB used_VBN individually_RB ,_, it_PRP
        would_MD require_VB the_DT immunostaining_VBG ,_, interpreting_VBG ,_, and_CC
        correlating_VBG of_IN nine_CD sections_NNS ._. In_IN contrast_NN to_TO this_DT ,_, the_DT
        cocktail_NN requires_VBZ only_RB three_CD sections_NNS ,_, each_DT at_IN intervals_NNS of_IN
        200_CD μ_NN ._. Thus_RB ,_, use_NN of_IN the_DT cocktail_NN in_IN concert_NN with_IN any_DT
        protocol_NN with_IN reference_NN to_TO number_NN of_IN sections_NNS to_TO be_VB
        evaluated_VBN and_CC proportion_NN of_IN sentinel_NN lymph_NN node_NN to_TO be_VB
        sampled_VBN [_NN 30_CD 31_CD ]_NN would_MD achieve_VB obvious_JJ cost_NN saving_NN ._.
        The_DT most_RBS ideal_JJ positive_JJ control_NN would_MD be_VB the_DT sausage_NN of_IN
        three_CD controls_NNS immunoreactive_JJ individually_RB for_IN one_CD of_IN the_DT
        antibodies_NNS but_CC non-immunoreactive_JJ for_IN other_JJ two_CD respective_JJ
        antibodies_NNS in_IN the_DT cocktail_NN ._. However_RB ,_, this_DT is_VBZ a_DT difficult_JJ
        positive_JJ control_NN to_TO get_VB ._. The_DT positive_JJ control_NN used_VBN by_IN us_PRP
        showed_VBD subtle_JJ differences_NNS when_WRB immunostained_JJ with_IN each_DT
        individual_JJ antibody_NN in_IN the_DT cocktail_NN with_IN some_DT areas_NNS
        slightly_RB darker_JJR than_IN others_NNS ._. However_RB ,_, when_WRB the_DT same_JJ control_NN
        was_VBD immunostained_JJ with_IN the_DT cocktail_NN ,_, the_DT entire_JJ control_NN
        showed_VBD relatively_RB homogeneous_JJ immunostaining_VBG ._. The_DT change_NN in_IN
        this_DT immunostaining_VBG pattern_NN would_MD suggest_VB the_DT deterioration_NN
        of_IN one_CD of_IN the_DT component_NN which_WDT can_MD be_VB correlated_JJ with_IN the_DT
        same_JJ control_NN immunostained_JJ with_IN the_DT individual_JJ antibodies_NNS ._.
        In_IN addition_NN ,_, another_DT precaution_NN taken_VBN by_IN us_PRP was_VBD that_IN the_DT
        cocktail_NN was_VBD prepared_VBN after_IN periodically_RB evaluating_VBG
        individual_JJ antibodies_NNS with_IN the_DT positive_JJ control_NN ._. This_DT later_JJ
        approach_NN is_VBZ the_DT best_JJS alternative_NN ._.
      
      
        Conclusions_NNP
        It_PRP is_VBZ possible_JJ to_TO use_VB a_DT combination_NN of_IN monoclonal_NN
        antibodies_NNS to_TO MART-_NNP 1_CD ,_, Melan-_NNP A_DT ,_, and_CC Tyrosinase_NNP as_IN a_DT single_JJ
        cocktail_NN reagent_NN on_IN one_CD glass_NN slide_NN in_IN contrast_NN to_TO three_CD
        individual_JJ antibodies_NNS on_IN three_CD slides_NNS ._. The_DT cocktail_NN
        facilitated_JJ easy_JJ detection_NN and_CC interpretation_NN of_IN melanoma_NN
        micrometastases_NNS in_IN sentinel_NN lymph_NN nodes_NNS with_IN reproducible_JJ
        inter-observer_JJ results_NNS ._. There_EX was_VBD favorable_JJ increase_NN in_IN the_DT
        detection_NN rate_NN of_IN melanoma_NN micrometastases_NNS in_IN sentinel_NN
        lymph_NN nodes_NNS as_IN compared_VBN to_TO MART-_NNP 1_CD and_CC Melan-_NNP A_DT individually_RB ._.
        Furthermore_RB ,_, this_DT approach_NN leads_VBZ to_TO obvious_JJ cost_NN savings_NNS
        and_CC simplifies_NNS the_DT interpretation_NN by_IN reducing_VBG the_DT number_NN of_IN
        slides_NNS to_TO be_VB evaluated_VBN ._.
      
      
        List_NN of_IN abbreviations_NNS
        AJCC_NNP ,_, American_NNP Joint_NNP Committee_NNP on_IN Cancer_NNP ;_: Az_NNP value_NN ,_, area_NN
        under_IN ROC_NNP curves_NNS ;_: DAB_NNP ,_, Diaminobenzidine_NNP Hydrochloride_NNP ;_: ROC_NNP
        curve_NN ,_, Receiver_NNP operating_VBG characteristic_JJ curve_NN ;_: S-_NNP 100_CD ,_,
        S-_NNP 100_CD protein_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        VS_NNP conceived_VBD ,_, designed_VBN ,_, carried_VBD out_RP the_DT entire_JJ study_NN in_IN
        addition_NN to_TO the_DT standardization_NN of_IN MCW_NNP melanoma_NN cocktail_NN
        protocol_NN and_CC preparation_NN of_IN manuscript_NN ._. DQ_NNP participated_VBD in_IN
        the_DT design_NN of_IN the_DT study_NN and_CC assisted_VBN in_IN data_NNS collection_NN ._. CC_NNP
        participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC performed_VBD the_DT
        statistical_JJ analysis_NN ._. RNR_NNP ,_, SA_NNP ,_, BK_NNP ,_, JM_NNP ,_, and_CC RK_NNP all_DT
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. GD_NNP performed_VBD
        the_DT immunohistochemical_JJ staining_VBG including_VBG standardization_NN
        of_IN the_DT MCW_NNP melanoma_NN cocktail_NN with_IN VS_NNP ._. All_DT authors_NNS read_VBP and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
